NCT03906006View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 17, 2018

Primary Completion Date

June 20, 2019

Study Completion Date

June 20, 2019

Conditions
GoutHyperuricemia
Interventions
DRUG

ABP-671

Drug: ABP-671, single oral dose

OTHER

Placebo

Other: Placebo, single oral dose

Trial Locations (1)

85283

Celerion, Tempe

Sponsors
All Listed Sponsors
lead

Atom Therapeutics Co., Ltd

INDUSTRY

NCT03906006 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects | Biotech Hunter | Biotech Hunter